Recombinant Human KLK2 (C-6His)

Recombinant Human KLK2 (C-6His)

Size1:10μg price1:$168
Size2:50μg price2:$465
Size3:500μg price3:$2350
SKU: PHH1033 Category: Target Proteins Tags: ,

Datasheet

Name

Recombinant Human KLK2 (C-6His)

Purity

Greater than 95% as determined by reducing SDS-PAGE

Endotoxin level

<0.01 EU/µg as determined by LAL test.

Construction

Recombinant Human Kallikrein 2 is produced by our Mammalian expression system and the target gene encoding Pro19-Pro261 is expressed with a 6His tag at the C-terminus.

Accession #

P20151

Host

Human Cells

Species

Human

Predicted Molecular Mass

27.9 KDa

Buffer

Supplied as a 0.2 μm filtered solution of 20mM Acetate, 250mM Trehalose, 0.02% Tween 80, pH5.0.

Form

Liquid

Shipping

The product is shipped on dry ice/polar packs.Upon receipt, store it immediately at the temperature listed below.

Stability&Storage

Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.

 

 

 

Alternative Names

Kallikrein-2; Glandular Kallikrein-1; hGK-1; Tissue Kallikrein-2; KLK2

 

Background

Kallikrein-2 (KLK2) is a secreted serine protease that belongs to the peptidase S1 family of Kallikrein subfamily. KLK2 contains 1 peptidase S1 domain. It is highly expressed in the human prostate gland. KLK2 can cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin, but Preferential cleavages of Arg-|-Xaa bonds in small molecule substrates. It also highly selective action to release kallidin (lysyl-bradykinin) from kininogen involves hydrolysis of Met-|-Xaa or Leu-|-Xaa. KLK2 is inhibited by serpins such as protein C inhibitor, antichymotrypsin, and plasminogen. KLK2 is considered to be a biomarker for prostate cancer.

 

Note

For Research Use Only , Not for Diagnostic Use.